Abstract 824P
Background
FLT3-ITD is one of the most common genetic abnormalities in acute myeloid leukemia (AML) and suggests a poor prognosis. The impact of FLT3-ITD on the immune microenvirenment requires further elucidation. Studies have shown that FLT3-ITD can significantly change the level of immune cells in the bone marrow in mice.
Methods
Flow cytometry was used to detect the CD47 mean fluorescent intensity (MFI). The FLT3 wildtype (FLT3-OE, FLT3 over expression) or ITD mutation (FLT3-ITD) stable overexpression K562/HEL cells were constructed by lentiviral transfections. The TRANSFAC database was used to predict the transcription factor binding sites of the CD47 promoter. We analyzed the location of CD47 gene on the chromosome, the sequence of promoter and first non-coding exon of HOXB5 via Jaspar online tool. The AML mouse model was constructed by injection of FLT3-ITD cells.
Results
LDH-induced macrophage killing was less in FLT3-ITD cell lines than FLT3-WT cell lines. Expression of CD47 can help protect tumor cells from attack by macrophages. The CD47 MFI of the FLT3-ITD group was higher than that of the control group. The CD47 MFI of the FLT3-ITD group was significantly higher than that of FLT3-OE group and FLT3 normal control (FLT3-NC) group. Flow cytometry results showed that FLT3-ITD impaired the activity of red-stained macrophages to phagocytizing green-stained K652/HEL cells. Using the TRANSFAC database, we found higher relative expression of CD47 gene in FLT3-ITD group than other groups and that HOXB5 may regulate the expression of CD47 at transcriptional level. Integrated analysis of Jasper online tool, dual luciferase reporter gene assay and ChIP experiment suggest that HOXB5 directly activate CD47. Compared with other groups, combination of CD47 inhibitor and FLT3-ITD inhibitor Quizartinib (AC220) significantly enhanced phagocytic activity of macrophages. The mouse model of AML further showed that combination of CD47 inhibitor and Quizartinib significantly reduced tumor burden in spleen and bone marrow.
Conclusions
Our data show that FLT3-ITD can induce immune escape to macrophages by upregulating CD47. Combination therapy with CD47 inhibitor and FLT3-ITD inhibitor can be promising for the treatment of FLT3-ITD AML.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Sun Yat-sen University Start-Up Funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
707P - Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study
Presenter: Edgar Israelyan
Session: Poster session 09
708P - The Empower Pathway: An audit of the first 150 patients. Enhanced personalised care of testicular cancer survivors
Presenter: Penny Champion
Session: Poster session 09
817P - A machine learning algorithm utilizing clinicopathologic parameters for extranodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 09
Resources:
Abstract
818P - The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy
Presenter: Z.L.Rana Kaplan
Session: Poster session 09
819P - Efficacy and safety of orelabrutinib plus R-CHOP-like regimens for treatment-naïve diffuse large B-cell lymphoma with double expression
Presenter: Wei Wan
Session: Poster session 09
820P - Second primary malignancies and disease transformation in symptomatic patients with Waldenstrom’s macroglobulinemia: Outcomes of a population-based analysis
Presenter: Vasiliki Spiliopoulou
Session: Poster session 09
821P - Circulating chromosomal alterations in lymphoid malignancies
Presenter: Rosalie Griffin
Session: Poster session 09
822P - Preliminary results from a phase Ib study of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Presenter: Lijuan Deng
Session: Poster session 09
823P - The bone marrow immune ecosystem shapes acquired resistance to daratumumab in plasma cell myeloma
Presenter: Yun Wang
Session: Poster session 09
825P - Ultra-sensitive cfDNA analysis for minimally invasive measurable residual disease detection and profiling in multiple myeloma
Presenter: Natalia Buenache
Session: Poster session 09